An analysis of DPV and DIVE registry patients with chronic kidney disease according to the finerenone phase III clinical trial selection criteria.
Albuminuria
Chronic kidney disease
Diabetes
Diabetic kidney disease
Diagnostics
Glomerular filtration rate
Hypertension
Pharmacotherapy
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
08 05 2023
08 05 2023
Historique:
received:
09
03
2023
accepted:
25
04
2023
medline:
11
5
2023
pubmed:
9
5
2023
entrez:
9
5
2023
Statut:
epublish
Résumé
The FIDELIO-DKD and FIGARO-DKD randomized clinical trials (RCTs) showed finerenone, a novel non-steroidal mineralocorticoid receptor antagonist (MRA), reduced the risk of renal and cardiovascular events in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). Using RCT inclusion and exclusion criteria, we analyzed the RCT coverage for patients with T2DM and CKD in routine clinical practice in Germany. German patients from the DPV/DIVE registries who were ≥ 18 years, had T2DM and CKD (an estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m Overall, 65,168 patients with T2DM and CKD were identified from DPV/DIVE. Key findings were (1) Registry patients with CKD were older, less often male, and had a lower eGFR, but more were normoalbuminuric vs the RCTs. Cardiovascular disease burden was higher in the RCTs; diabetic neuropathy, lipid metabolism disorders, and peripheral arterial disease were more frequent in the registry. CKD-specific drugs (e.g., angiotensin-converting enzyme inhibitors [ACEi] and angiotensin receptor blocker [ARBs]) were used less often in clinical practice; (2) Due to the RCT's albuminuric G1/2 to G4 CKD focus, they did not cover 28,147 (43.2%) normoalbuminuric registry patients, 4,519 (6.9%) albuminuric patients with eGFR < 25, and 6,565 (10.1%) patients with microalbuminuria but normal GFR (≥ 90 ml/min); 3) As RCTs required baseline ACEi or ARB treatment, the number of comparable registry patients was reduced to 28,359. Of these, only 12,322 (43.5%) registry patients fulfilled all trial inclusion and exclusion criteria. Registry patients that would have been eligible for the RCTs were more often male, had higher eGFR values, higher rates of albuminuria, more received metformin, and more SGLT-2 inhibitors than patients that would not be eligible. Certain patient subgroups, especially non-albuminuric CKD-patients, were not included in the RCTs. Although recommended by guidelines, there was an undertreatment of CKD-patients with renin-angiotensin system (RAS) blockers. Further research into patients with normoalbuminuric CKD and a wider prescription of RAS blocking agents for CKD patients in clinical practice appears warranted.
Sections du résumé
BACKGROUND
The FIDELIO-DKD and FIGARO-DKD randomized clinical trials (RCTs) showed finerenone, a novel non-steroidal mineralocorticoid receptor antagonist (MRA), reduced the risk of renal and cardiovascular events in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). Using RCT inclusion and exclusion criteria, we analyzed the RCT coverage for patients with T2DM and CKD in routine clinical practice in Germany.
METHODS
German patients from the DPV/DIVE registries who were ≥ 18 years, had T2DM and CKD (an estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m
RESULTS
Overall, 65,168 patients with T2DM and CKD were identified from DPV/DIVE. Key findings were (1) Registry patients with CKD were older, less often male, and had a lower eGFR, but more were normoalbuminuric vs the RCTs. Cardiovascular disease burden was higher in the RCTs; diabetic neuropathy, lipid metabolism disorders, and peripheral arterial disease were more frequent in the registry. CKD-specific drugs (e.g., angiotensin-converting enzyme inhibitors [ACEi] and angiotensin receptor blocker [ARBs]) were used less often in clinical practice; (2) Due to the RCT's albuminuric G1/2 to G4 CKD focus, they did not cover 28,147 (43.2%) normoalbuminuric registry patients, 4,519 (6.9%) albuminuric patients with eGFR < 25, and 6,565 (10.1%) patients with microalbuminuria but normal GFR (≥ 90 ml/min); 3) As RCTs required baseline ACEi or ARB treatment, the number of comparable registry patients was reduced to 28,359. Of these, only 12,322 (43.5%) registry patients fulfilled all trial inclusion and exclusion criteria. Registry patients that would have been eligible for the RCTs were more often male, had higher eGFR values, higher rates of albuminuria, more received metformin, and more SGLT-2 inhibitors than patients that would not be eligible.
CONCLUSIONS
Certain patient subgroups, especially non-albuminuric CKD-patients, were not included in the RCTs. Although recommended by guidelines, there was an undertreatment of CKD-patients with renin-angiotensin system (RAS) blockers. Further research into patients with normoalbuminuric CKD and a wider prescription of RAS blocking agents for CKD patients in clinical practice appears warranted.
Identifiants
pubmed: 37158855
doi: 10.1186/s12933-023-01840-5
pii: 10.1186/s12933-023-01840-5
pmc: PMC10169333
doi:
Substances chimiques
finerenone
0
Angiotensin-Converting Enzyme Inhibitors
0
Types de publication
Clinical Trial, Phase III
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108Informations de copyright
© 2023. The Author(s).
Références
Cardiovasc Diabetol. 2016 May 03;15:72
pubmed: 27141979
J Am Heart Assoc. 2022 Apr 5;11(7):e025079
pubmed: 35311349
Nat Rev Nephrol. 2018 Jun;14(6):361-377
pubmed: 29654297
N Engl J Med. 2001 Sep 20;345(12):851-60
pubmed: 11565517
Br J Clin Pharmacol. 2004 Jan;57(1):86-92
pubmed: 14678345
J Nephrol. 2020 Feb;33(1):9-35
pubmed: 31576500
Healthcare (Basel). 2021 May 13;9(5):
pubmed: 34068355
Dtsch Med Wochenschr. 2013 May;138(18):934-9
pubmed: 23613371
BMC Nephrol. 2021 May 19;22(1):184
pubmed: 34011313
Am J Nephrol. 2019;50(5):345-356
pubmed: 31665733
J Diabetes Complications. 2017 Sep;31(9):1376-1383
pubmed: 28711195
PLoS One. 2016 Jan 26;11(1):e0147329
pubmed: 26812415
N Engl J Med. 2003 Aug 28;349(9):868-74
pubmed: 12944573
Kidney Int Suppl (2011). 2013 Jan;3(1):19-62
pubmed: 25018975
Eur Heart J. 2022 Feb 10;43(6):474-484
pubmed: 35023547
N Engl J Med. 2020 Oct 8;383(15):1436-1446
pubmed: 32970396
Eur Heart J. 2021 Jul 1;42(25):2439-2454
pubmed: 34120177
Eur Heart J. 2020 Jan 7;41(2):255-323
pubmed: 31497854
BMC Res Notes. 2014 Jul 02;7:415
pubmed: 24990184
J Am Soc Nephrol. 2009 Aug;20(8):1813-21
pubmed: 19443635
Nephrol Dial Transplant. 2022 Jun 23;37(7):1317-1329
pubmed: 35238940
Kidney Int. 2006 Nov;70(10):1694-705
pubmed: 16969387
Cardiovasc Diabetol. 2019 Mar 16;18(1):33
pubmed: 30878037
J Am Coll Cardiol. 2017 Nov 14;70(20):2476-2486
pubmed: 29141781
Nat Clin Pract Nephrol. 2007 Sep;3(9):486-92
pubmed: 17717561
Int J Mol Sci. 2021 May 21;22(11):
pubmed: 34063872
J Diabetes Complications. 2018 Mar;32(3):291-297
pubmed: 29352693
Clin J Am Soc Nephrol. 2017 Dec 7;12(12):2032-2045
pubmed: 28522654
Am J Kidney Dis. 2008 Feb;51(2):199-211
pubmed: 18215698
Am J Kidney Dis. 2009 Jun;53(6):925-7
pubmed: 19463760
N Engl J Med. 2019 Jun 13;380(24):2295-2306
pubmed: 30990260
Diabetes. 1983 May;32 Suppl 2:64-78
pubmed: 6400670
N Engl J Med. 2001 Sep 20;345(12):861-9
pubmed: 11565518
Am J Med Sci. 2015 Jun;349(6):510-5
pubmed: 26030613
J Am Geriatr Soc. 2013 May;61(5):734-8
pubmed: 23590338
N Engl J Med. 1993 Nov 11;329(20):1456-62
pubmed: 8413456
N Engl J Med. 2020 Dec 03;383(23):2219-2229
pubmed: 33264825
N Engl J Med. 2021 Dec 9;385(24):2252-2263
pubmed: 34449181
J Nephropharmacol. 2015 Oct 09;5(1):49-56
pubmed: 28197499
Kidney Int. 2018 Sep;94(3):567-581
pubmed: 30078514
Clin Ther. 2015 Jan 1;37(1):188-96
pubmed: 25524390
Am J Nephrol. 2017 Dec 13;46(6):462-472
pubmed: 29253846
J Am Geriatr Soc. 2017 Nov;65(11):2354-2361
pubmed: 28306144
J Pediatr. 2015 Dec;167(6):1436-9
pubmed: 26427965
N Engl J Med. 2008 Feb 7;358(6):580-91
pubmed: 18256393
Kidney360. 2021 Feb 01;2(4):742-746
pubmed: 35373039
Am J Nephrol. 2019;50(5):333-344
pubmed: 31655812
Kidney Int. 2011 Jul;80(1):17-28
pubmed: 21150873
Nephrol Dial Transplant. 2020 Oct 1;35(10):1700-1711
pubmed: 32862232
Ann Intern Med. 2013 Jun 4;158(11):825-30
pubmed: 23732715